EU talks with Pfizer, Sanofi, J&J on Covid vaccines hit snags - sources
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
THURSDAY, MAY 19, 2022
THURSDAY, MAY 19, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
EU talks with Pfizer, Sanofi, J&J on Covid vaccines hit snags - sources

Coronavirus chronicle

Reuters
27 July, 2020, 09:15 pm
Last modified: 27 July, 2020, 09:20 pm

Related News

  • How the Northern Ireland protocol divides Britain and the EU
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot
  • Pfizer eyes Covid vaccine for all variants before 2023
  • EU says resuming diplomatic presence in Kyiv

EU talks with Pfizer, Sanofi, J&J on Covid vaccines hit snags - sources

The United States, meanwhile, has already inked two supply agreements with AstraZeneca and Pfizer among other major funding deals

Reuters
27 July, 2020, 09:15 pm
Last modified: 27 July, 2020, 09:20 pm
Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020/ Reuters
Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020/ Reuters

European efforts to secure potential Covid-19 vaccines from Pfizer, Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.

The bloc is in talks with at least six vaccine makers to acquire up front doses of potential shots against the novel coronavirus, officials told Reuters earlier in July, in a strategy meant to increase the chances of having Covid-19 vaccines for its population.

Despite the urgency to seal deals amid a global race to secure the most promising shots, the EU is struggling to reach swift agreements, said the officials, who are involved in the talks, and declined to be named because the negotiations are confidential.

The United States, meanwhile, has already inked two supply agreements with AstraZeneca and Pfizer among other major funding deals.

The EU's negotiations with Johnson & Johnson are among the most advanced but have yet to conclude amid a back-and-forth over how to share liability costs if the potential vaccine showed unexpected side-effects, two of the officials told Reuters.

Johnson & Johnson had no immediate comment.

France's Sanofi is negotiating to supply 300 million doses of the potential vaccine it is developing with British drugmaker GlaxoSmithKline Plc to the EU and wants an immediate upfront payment for the entire stock, two officials said.

But the EU wants to pay in tranches and delay some payments until the vaccine has passed large clinical trials, the officials said.

This has caused "some hurdles," one of the officials said.

A spokesman for Sanofi declined to comment.

A spokesman for the Commission, which is leading EU talks with drugmakers, declined to comment.

Aside from the Pfizer, Sanofi and Johnson & Johnson discussions, the EU is also in talks with biotech companies Moderna and Germany's CureVac, officials told Reuters earlier in July.

Moderna and CureVac were not immediately available to comment.

A deal with AstraZeneca for its vaccine under development with Oxford University was struck by four large EU countries in June and is now about to be completed for the whole 27-nation bloc, officials said.

One official said the EU was seeking to seal three or four advance purchase deals.

"OVER BUDGET"

The most complex talks appear to be with Pfizer and BioNtech which are developing a vaccine using an experimental technology known as messenger RNA, or mRNA, which has not been approved for commercial use by medical authorities.

The two firms want the EU to pay them for 500 million doses only if their Covid-19 vaccine is authorised, one official told Reuters.

This might eliminate the EU's risk of losing money should the shot prove unsuccessful. But the bloc fears that if it waits for the vaccine to be proved effective, the bill could be much higher and they risk going "over budget," one of the officials said.

In a further potential complication, some EU negotiators have raised doubts about mRNA, which is also used in the potential Covid vaccines developed by Moderna and CureVac.

Pfizer and BioNtech are also discussing liability issues with EU negotiators, a fourth person familiar with the talks told Reuters.

Pfizer and BioNTech declined to comment.

The U.S. government last week agreed to pay nearly $2 billion to buy enough of the vaccine being developed by Pfizer and BioNTech to inoculate 50 million people, but with payments conditional on their vaccine being successful in large clinical trials.

The price agreed under that deal of nearly $40 per course of treatment is considered too high by the EU, officials told Reuters last week.

The EU is relying on about 2 billion euros ($2.3 billion) from an emergency fund to finance its possible deals with vaccine makers, which could be topped up with payments from EU governments.

For instance, the agreement with AstraZeneca initially negotiated by Germany, France, Italy and the Netherlands cost the four countries 750 million euros for 300 million doses of the potential shot, an Italian official said, with an option to buy a further 100 million doses.

That works out at 2.5 euros per dose.

It is not clear whether under ongoing talks that money will now be provided by the EU emergency fund.

($1 = 0.8581 euros)

Top News / World+Biz

European Union / Johnson & Johnson / Pfizer Inc / Sanofi / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Illustration: TBS
    Let taka slide
  • Nearly 58% hike in bulk power price on cards
    Nearly 58% hike in bulk power price on cards
  • Inflation jumps to 6.29% in April
    Inflation jumps to 6.29% in April

MOST VIEWED

  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial
  • A woman wearing protective mask walks at a sidewalk near business district in Jakarta, Indonesia March 2, 2020. REUTERS/Willy Kurniawan/Files
    Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • North Korean leader Kim Jong Un presides over a politburo meeting of the ruling Workers' Party, amid the coronavirus disease (COVID-19) pandemic, May 17, 2022, in this photo released May 18, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO
    North Korea Covid outbreak is 'worrying' for new variants -WHO
  • People watch a TV broadcasting a news report on the coronavirus disease (Covid-19) outbreak in North Korea, at a railway station in Seoul, South Korea on 17 May 2022. Photo: Reuters.
    N Korea Covid outbreak could have 'devastating' impact on human rights, UN says
  • Two women hug at a closed street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 16, 2022. REUTERS/Aly Song
    Shanghai achieves 'zero Covid' status but normal life is weeks away

Related News

  • How the Northern Ireland protocol divides Britain and the EU
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot
  • Pfizer eyes Covid vaccine for all variants before 2023
  • EU says resuming diplomatic presence in Kyiv

Features

Illustration: TBS

‘Do you have insurance?’: Life of a life insurance agent

22m | Panorama
‘The geopolitical landscape is undergoing profound change, Dhaka needs to craft proactive strategies’

‘The geopolitical landscape is undergoing profound change, Dhaka needs to craft proactive strategies’

23h | Interviews
Graphics: TBS

Facebook and Bangladeshi politicians: A new tide in mass political communication?

1d | Panorama
Despite Bangladesh having about 24,000 km of waterways, only a few hundred kilometres are covered by commercial launch services. Photo: Saad Abdullah

Utilising waterways: When common home-goers show the way

1d | Panorama

More Videos from TBS

Cannes Film Festival 2022 resumes after 2 years

Cannes Film Festival 2022 resumes after 2 years

12h | Videos
Pension is coming for all

Pension is coming for all

12h | Videos
Bakery business in crisis for increased raw material prices

Bakery business in crisis for increased raw material prices

14h | Videos
Foods that have the most protein

Foods that have the most protein

14h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

5
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

6
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab